ALK-Abelló
ALK-Abello A/S is a Danish pharmaceutical company specializing in allergy immunotherapy and allergy prevention. The company researches, produces, and commercializes sublingual and subcutaneous allergy vaccines, sublingual allergy immunotherapy tablets, and emergency adrenaline auto-injectors. Main revenue drivers include global commercial sales of allergy tablets for house dust mite, grass, and tree pollen allergies alongside emergency adrenaline treatments. ALK-Abello serves allergy specialists, ENT doctors, clinical immunologists, and allergic patients across Europe, North America, and Asia-Pacific. The company holds a world-leading market position as the global leader in allergy immunotherapy treatments. Headquartered in Horsholm, Denmark, ALK-Abello A/S is listed on Nasdaq Copenhagen.
38 of the funds FundTelligence covers report a position in ALK-Abelló.
- Sector
- Health Care
- Country
- Denmark
- Funds holding it
- 38
Funds holding ALK-Abelló
- Danske Invest Denmark Focus — Danske Invest · 3.47 % (full portfolio disclosed, September 2026)
- Nordea Danmark — Nordea Funds · 3.25 % (full portfolio disclosed, September 2026)
- Alfred Berg Nordic Small Cap — Alfred Berg · 3.14 % (full portfolio disclosed, June 2026)
- BNP Nordic Small Cap — BNP Paribas · 2.97 % (full portfolio disclosed, June 2026)
- Nordea Danske aktier fokus — Nordea Funds · 2.75 % (full portfolio disclosed, September 2026)
- DWS Invest ESG Climate Opportunities — DWS · 2.29 % (full portfolio disclosed, June 2026)
- Swedbank Robur Småbolagsfond Norden — Swedbank · 2.07 % (full portfolio disclosed, October 2026)
- Schroder ISF Nordic Smaller Companies — Schroders · 1.62 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 38 funds holding it.